Bucindolol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bucindolol
Accession Number
DB12752
Type
Small Molecule
Groups
Investigational
Description

Bucindolol has been investigated in Heart Failure.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
E9UO06K7CE
CAS number
71119-11-4
Weight
Average: 363.461
Monoisotopic: 363.194677057
Chemical Formula
C22H25N3O2
InChI Key
FBMYKMYQHCBIGU-UHFFFAOYSA-N
InChI
InChI=1S/C22H25N3O2/c1-22(2,11-17-13-24-20-9-5-4-8-19(17)20)25-14-18(26)15-27-21-10-6-3-7-16(21)12-23/h3-10,13,18,24-26H,11,14-15H2,1-2H3
IUPAC Name
2-(2-hydroxy-3-{[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino}propoxy)benzonitrile
SMILES
CC(C)(CC1=CNC2=CC=CC=C12)NCC(O)COC1=CC=CC=C1C#N

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Bucindolol.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bucindolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Experimental, Illicit
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Bucindolol.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Bucindolol.Approved, Experimental, Investigational
AcepromazineAcepromazine may increase the hypotensive activities of Bucindolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bucindolol.Approved
AcetohexamideBucindolol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Bucindolol is combined with Acetylcholine.Approved
AcetyldigitoxinBucindolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinBucindolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bucindolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bucindolol.Approved
AdrafinilBucindolol may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Experimental, Investigational
AlaproclateThe serum concentration of Bucindolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Bucindolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Bucindolol.Approved, Illicit
AlfuzosinBucindolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bucindolol.Approved, Vet Approved
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Bucindolol.Experimental
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Bucindolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Bucindolol.Approved
AmibegronBucindolol may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneThe therapeutic efficacy of Bucindolol can be increased when used in combination with Amiodarone.Approved, Investigational
AmitrazBucindolol may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmlodipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Amlodipine.Approved
AmobarbitalThe serum concentration of Bucindolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Bucindolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Bucindolol.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Bucindolol is combined with Amrinone.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Bucindolol.Investigational
AnisodamineBucindolol may decrease the vasoconstricting activities of Anisodamine.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Bucindolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
ApraclonidineBucindolol may decrease the vasoconstricting activities of Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
ArbutamineBucindolol may decrease the vasoconstricting activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Bucindolol is combined with Arecoline.Experimental
ArformoterolBucindolol may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Bucindolol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Bucindolol.Approved
AvanafilAvanafil may increase the hypotensive activities of Bucindolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bucindolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bucindolol.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Bucindolol is combined with Azimilide.Investigational
BalsalazideBalsalazide may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
BarbexacloneThe serum concentration of Bucindolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Bucindolol can be decreased when it is combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Bucindolol.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Bucindolol is combined with Bencyclane.Experimental
BendazacBendazac may decrease the antihypertensive activities of Bucindolol.Experimental
BenidipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Benidipine.Approved, Investigational
BenorilateBenorilate may decrease the antihypertensive activities of Bucindolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bucindolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Bucindolol.Approved
BepridilThe risk or severity of hypotension can be increased when Bucindolol is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Bucindolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Bucindolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Bucindolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Bucindolol.Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Bucindolol.Approved
BitolterolBucindolol may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BL-1020BL-1020 may increase the hypotensive activities of Bucindolol.Investigational
BopindololBopindolol may increase the orthostatic hypotensive activities of Bucindolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Bucindolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Bucindolol.Approved, Experimental
BufuralolBufuralol may increase the orthostatic hypotensive activities of Bucindolol.Experimental, Investigational
BumadizoneBumadizone may decrease the antihypertensive activities of Bucindolol.Experimental
BunazosinBucindolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bucindolol.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Bucindolol.Approved
CabergolineBucindolol may increase the vasoconstricting activities of Cabergoline.Approved
CarbacholThe risk or severity of adverse effects can be increased when Bucindolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Bucindolol.Experimental, Investigational
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Bucindolol is combined with Carboxyamidotriazole.Investigational
CarbutamideBucindolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroverineThe risk or severity of hypotension can be increased when Bucindolol is combined with Caroverine.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Bucindolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Bucindolol.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive activities of Bucindolol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bucindolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Bucindolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Bucindolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bucindolol can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Bucindolol.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Bucindolol.Experimental
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bucindolol.Approved, Investigational, Vet Approved
ChlorpropamideBucindolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Bucindolol.Approved
CilnidipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Bucindolol is combined with Cinnarizine.Approved, Investigational
CirazolineBucindolol may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Bucindolol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Clevidipine.Approved, Investigational
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bucindolol.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Bucindolol.Experimental
CoumaphosCoumaphos may increase the bradycardic activities of Bucindolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Bucindolol is combined with Cyclandelate.Approved
CymarinBucindolol may increase the bradycardic activities of Cymarin.Experimental
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Bucindolol.Investigational
DarodipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Darodipine.Experimental
DecamethoniumDecamethonium may increase the bradycardic activities of Bucindolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Bucindolol.Approved
DeslanosideBucindolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bucindolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DetomidineBucindolol may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Bucindolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bucindolol.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Bucindolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
DigitoxinBucindolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinBucindolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Bucindolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Bucindolol.Approved, Investigational
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bucindolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bucindolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Bucindolol.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Bucindolol.Approved
DonepezilDonepezil may increase the bradycardic activities of Bucindolol.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Bucindolol.Approved
DopexamineBucindolol may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DotarizineThe risk or severity of hypotension can be increased when Bucindolol is combined with Dotarizine.Investigational
DoxazosinBucindolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Bucindolol is combined with Doxofylline.Approved, Investigational
DronabinolDronabinol may increase the tachycardic activities of Bucindolol.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Bucindolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bucindolol.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
DuloxetineThe serum concentration of Bucindolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bucindolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Bucindolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bucindolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bucindolol.Approved
EfonidipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Efonidipine.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Bucindolol.Experimental
EperisoneThe risk or severity of hypotension can be increased when Bucindolol is combined with Eperisone.Approved, Investigational
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Nutraceutical, Withdrawn
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Bucindolol.Approved
EpibatidineThe risk or severity of adverse effects can be increased when Bucindolol is combined with Epibatidine.Experimental
EpinastineBucindolol may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bucindolol.Approved
Ergoloid mesylateBucindolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBucindolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Bucindolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Bucindolol.Experimental
EthosuximideThe risk or severity of hypotension can be increased when Bucindolol is combined with Ethosuximide.Approved
EtilefrineThe risk or severity of adverse effects can be increased when Etilefrine is combined with Bucindolol.Withdrawn
EtodolacEtodolac may decrease the antihypertensive activities of Bucindolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved
EtoperidoneThe serum concentration of Bucindolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
ExisulindExisulind may decrease the antihypertensive activities of Bucindolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Bucindolol.Experimental
FelodipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Bucindolol.Approved
FendilineThe risk or severity of hypotension can be increased when Bucindolol is combined with Fendiline.Withdrawn
FenoprofenFenoprofen may decrease the antihypertensive activities of Bucindolol.Approved
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Bucindolol.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Bucindolol is combined with Fenozolone.Experimental
FentanylFentanyl may increase the bradycardic activities of Bucindolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bucindolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Bucindolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Bucindolol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Bucindolol.Experimental
FingolimodBucindolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Bucindolol is combined with Floctafenine.Approved, Withdrawn
FlunarizineThe risk or severity of hypotension can be increased when Bucindolol is combined with Flunarizine.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Bucindolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Bucindolol.Experimental
FluoxetineThe serum concentration of Bucindolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Bucindolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
FluspirileneThe risk or severity of hypotension can be increased when Bucindolol is combined with Fluspirilene.Approved, Investigational
FormoterolBucindolol may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Bucindolol is combined with Gabapentin.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Bucindolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bucindolol.Approved
GallopamilThe risk or severity of hypotension can be increased when Bucindolol is combined with Gallopamil.Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bucindolol.Approved, Investigational, Nutraceutical
GitoformateBucindolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideBucindolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideBucindolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBucindolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBucindolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneBucindolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideBucindolol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideBucindolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bucindolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Bucindolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
HexobarbitalThe serum concentration of Bucindolol can be decreased when it is combined with Hexobarbital.Approved
HexoprenalineBucindolol may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineBucindolol may decrease the vasoconstricting activities of Higenamine.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bucindolol.Approved, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Bucindolol.Approved
HydroxychloroquineThe metabolism of Bucindolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bucindolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bucindolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Bucindolol.Experimental
IndalpineThe serum concentration of Bucindolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndenololIndenolol may increase the orthostatic hypotensive activities of Bucindolol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Bucindolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bucindolol.Withdrawn
IndoraminBucindolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanBucindolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkBucindolol may increase the hypoglycemic activities of Insulin Pork.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Bucindolol.Approved, Investigational
IpidacrineIpidacrine may increase the bradycardic activities of Bucindolol.Experimental
IsoetarineBucindolol may decrease the vasoconstricting activities of Isoetarine.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Bucindolol.Approved, Investigational, Withdrawn
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Bucindolol.Approved, Investigational
IsoxicamIsoxicam may decrease the antihypertensive activities of Bucindolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Bucindolol.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Isradipine.Approved, Investigational
KebuzoneKebuzone may decrease the antihypertensive activities of Bucindolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Bucindolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bucindolol.Approved
LabetalolLabetalol may increase the orthostatic hypotensive activities of Bucindolol.Approved
LacidipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Bucindolol is combined with Lamotrigine.Approved, Investigational
Lanatoside CBucindolol may increase the bradycardic activities of Lanatoside C.Experimental
LandiololLandiolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Bucindolol is combined with Levetiracetam.Approved, Investigational
LevomilnacipranThe serum concentration of Bucindolol can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bucindolol.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Bucindolol is combined with Lidoflazine.Experimental
LinezolidLinezolid may increase the hypertensive activities of Bucindolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Bucindolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bucindolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Bucindolol.Experimental
LoperamideThe risk or severity of hypotension can be increased when Bucindolol is combined with Loperamide.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bucindolol.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Bucindolol is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
MalathionMalathion may increase the bradycardic activities of Bucindolol.Approved, Investigational
ManidipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Manidipine.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bucindolol.Approved, Vet Approved
MedetomidineBucindolol may decrease the vasoconstricting activities of Medetomidine.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bucindolol.Approved
MefenorexThe risk or severity of adverse effects can be increased when Bucindolol is combined with Mefenorex.Experimental
MefloquineMefloquine may increase the bradycardic activities of Bucindolol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Bucindolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bucindolol.Approved, Investigational
MephentermineBucindolol may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Bucindolol.Experimental
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bucindolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bucindolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bucindolol.Approved, Investigational
MetahexamideBucindolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Bucindolol.Approved, Investigational, Withdrawn
MetaraminolBucindolol may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethacholineBucindolol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bucindolol.Investigational
MethohexitalThe serum concentration of Bucindolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bucindolol.Approved, Investigational
MethoxamineBucindolol may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineBucindolol may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Bucindolol is combined with Methsuximide.Approved
MethyldopaBucindolol may decrease the vasoconstricting activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bucindolol.Approved, Investigational
MethylergometrineBucindolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalThe serum concentration of Bucindolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinBucindolol may increase the bradycardic activities of Metildigoxin.Experimental
MetoclopramideMetoclopramide may increase the bradycardic activities of Bucindolol.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Bucindolol.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Bucindolol is combined with Mibefradil.Investigational, Withdrawn
MidodrineBucindolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Bucindolol can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Bucindolol.Approved
MirabegronBucindolol may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Bucindolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Bucindolol.Investigational
MofebutazoneMofebutazone may decrease the antihypertensive activities of Bucindolol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Bucindolol.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bucindolol.Approved
NabiloneNabilone may increase the tachycardic activities of Bucindolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Bucindolol.Approved
NadololNadolol may increase the orthostatic hypotensive activities of Bucindolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Bucindolol.Approved
NaftopidilThe risk or severity of hypotension can be increased when Bucindolol is combined with Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bucindolol.Approved, Vet Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Bucindolol.Approved, Investigational
NefazodoneThe serum concentration of Bucindolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Bucindolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
NicardipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Nicardipine.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Bucindolol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bucindolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Bucindolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bucindolol.Approved
NiguldipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Bucindolol is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Bucindolol is combined with Nitrendipine.Approved, Investigational
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bucindolol.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved
NorfenefrineBucindolol may decrease the vasoconstricting activities of Norfenefrine.Experimental
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Bucindolol.Approved
OctopamineBucindolol may decrease the vasoconstricting activities of Octopamine.Experimental
OleandrinBucindolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlodaterolBucindolol may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Bucindolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bucindolol.Approved
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Bucindolol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bucindolol.Vet Approved
OtiloniumThe risk or severity of hypotension can be increased when Bucindolol is combined with Otilonium.Experimental, Investigational
OuabainBucindolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bucindolol.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Bucindolol.Approved
OxyfedrineBucindolol may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bucindolol.Approved, Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved
ParaoxonParaoxon may increase the bradycardic activities of Bucindolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Bucindolol.Approved
ParoxetineThe serum concentration of Bucindolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Bucindolol.Approved, Investigational
PentobarbitalThe serum concentration of Bucindolol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerazinePerazine may increase the hypotensive activities of Bucindolol.Approved, Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Bucindolol.Approved
PeruvosideBucindolol may increase the bradycardic activities of Peruvoside.Experimental
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Bucindolol.Approved, Illicit
PhenobarbitalThe serum concentration of Bucindolol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Bucindolol.Approved, Illicit
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bucindolol.Approved, Vet Approved
PhenylephrineBucindolol may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Bucindolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Bucindolol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Bucindolol is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
PinaveriumThe risk or severity of hypotension can be increased when Bucindolol is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Bucindolol.Approved, Investigational
PirbuterolBucindolol may decrease the vasoconstricting activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Bucindolol.Experimental
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Bucindolol.Experimental
PractololPractolol may increase the orthostatic hypotensive activities of Bucindolol.Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Bucindolol.Experimental, Investigational
PrazosinBucindolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Bucindolol is combined with Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Bucindolol is combined with Prenylamine.Withdrawn
PrimaquineThe metabolism of Bucindolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Bucindolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Bucindolol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bucindolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Bucindolol.Experimental
PromazinePromazine may increase the hypotensive activities of Bucindolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bucindolol.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
PropafenoneThe serum concentration of Bucindolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Bucindolol.Approved, Investigational
PropiopromazinePropiopromazine may increase the hypotensive activities of Bucindolol.Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Bucindolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Bucindolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Bucindolol.Experimental
ProscillaridinBucindolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bucindolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bucindolol.Approved, Investigational
RacepinephrineThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Bucindolol.Approved
RactopamineBucindolol may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RegorafenibRegorafenib may increase the bradycardic activities of Bucindolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Bucindolol.Approved
ReproterolBucindolol may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineReserpine may increase the hypotensive activities of Bucindolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Bucindolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Bucindolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bucindolol can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Bucindolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineBucindolol may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolBucindolol may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
RitobegronBucindolol may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Bucindolol.Approved, Investigational
RivastigmineBucindolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bucindolol.Approved, Investigational, Withdrawn
RomifidineBucindolol may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
SalbutamolBucindolol may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Bucindolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bucindolol.Approved, Investigational, Vet Approved
SalmeterolBucindolol may decrease the vasoconstricting activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bucindolol.Approved
SecobarbitalThe serum concentration of Bucindolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Bucindolol is combined with Seletracetam.Investigational
SemapimodSemapimod may decrease the antihypertensive activities of Bucindolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Bucindolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Bucindolol.Investigational
SertralineThe serum concentration of Bucindolol can be increased when it is combined with Sertraline.Approved
SildenafilSildenafil may increase the hypotensive activities of Bucindolol.Approved, Investigational
SilodosinBucindolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SolabegronBucindolol may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Bucindolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bucindolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Bucindolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bucindolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Bucindolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Bucindolol.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Synephrine is combined with Bucindolol.Experimental
TacrineTacrine may increase the bradycardic activities of Bucindolol.Investigational, Withdrawn
TadalafilTadalafil may increase the hypotensive activities of Bucindolol.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
TamsulosinBucindolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Bucindolol.Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Bucindolol.Approved
TenidapTenidap may decrease the antihypertensive activities of Bucindolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Bucindolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bucindolol.Vet Approved
TerazosinBucindolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Bucindolol.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bucindolol.Approved
TerodilineThe risk or severity of hypotension can be increased when Bucindolol is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Bucindolol.Experimental
TetrahydropalmatineThe risk or severity of hypotension can be increased when Bucindolol is combined with Tetrahydropalmatine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Bucindolol.Approved
ThiamylalThe serum concentration of Bucindolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Bucindolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bucindolol.Withdrawn
ThiopentalThe serum concentration of Bucindolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Bucindolol.Approved
ThioridazineThioridazine may increase the hypotensive activities of Bucindolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bucindolol.Approved
TimololTimolol may increase the orthostatic hypotensive activities of Bucindolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bucindolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
TolazamideBucindolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideBucindolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of hypotension can be increased when Bucindolol is combined with Tolfenamic Acid.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Bucindolol.Approved
TramazolineThe risk or severity of adverse effects can be increased when Bucindolol is combined with Tramazoline.Investigational
TranilastThe risk or severity of hypotension can be increased when Bucindolol is combined with Tranilast.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Bucindolol is combined with Tretoquinol.Experimental
TribenosideTribenoside may decrease the antihypertensive activities of Bucindolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Bucindolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bucindolol.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Bucindolol.Approved, Vet Approved
TrimazosinBucindolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Bucindolol is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Bucindolol is combined with Trimethadione.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Bucindolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Bucindolol.Approved
TulobuterolBucindolol may decrease the vasoconstricting activities of Tulobuterol.Investigational
TyramineThe risk or severity of adverse effects can be increased when Tyramine is combined with Bucindolol.Investigational, Nutraceutical
UdenafilUdenafil may increase the hypotensive activities of Bucindolol.Approved, Investigational
UrapidilBucindolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bucindolol.Approved, Investigational, Withdrawn
VardenafilVardenafil may increase the hypotensive activities of Bucindolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Bucindolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Bucindolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Bucindolol.Approved
VinpocetineThe risk or severity of hypotension can be increased when Bucindolol is combined with Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Bucindolol is combined with WIN 55212-2.Experimental
XamoterolBucindolol may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazineBucindolol may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bucindolol.Approved, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Bucindolol is combined with Ziconotide.Approved
ZileutonZileuton may decrease the antihypertensive activities of Bucindolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bucindolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Bucindolol.Withdrawn
ZonisamideThe risk or severity of hypotension can be increased when Bucindolol is combined with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
51045
PubChem Substance
347828941
ChemSpider
46266
BindingDB
50169808
ChEMBL
CHEMBL321582
PharmGKB
PA165945764

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentCurrent or Recent History of Atrial Fibrillation1
Not AvailableUnknown StatusNot AvailableHeart Failure, Unspecified1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00744 mg/mLALOGPS
logP3.4ALOGPS
logP3.49ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.69ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area81.07 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity106.44 m3·mol-1ChemAxon
Polarizability39.98 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indoles
Direct Parent
3-alkylindoles
Alternative Parents
Phenoxy compounds / Phenol ethers / Benzonitriles / Aralkylamines / Alkyl aryl ethers / Substituted pyrroles / Heteroaromatic compounds / Secondary alcohols / 1,2-aminoalcohols / Nitriles
show 4 more
Substituents
3-alkylindole / Phenoxy compound / Benzonitrile / Phenol ether / Alkyl aryl ether / Aralkylamine / Monocyclic benzene moiety / Benzenoid / Substituted pyrrole / Heteroaromatic compound
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 18:01 / Updated on December 01, 2017 16:33